Metabolic encephalopathy can be a potentially life-threatening complication from valproic acid;Metabole encefalopathie als potentieel levensbedreigende complicatie van valproïnezuur

Nederlands Tijdschrift voor Geneeskunde

Volumn 152, Issue 5, 2008, Pages 278-282

  Meinardi, M C ^a   Van Den Berg, G B ^a   Groenhuijzen, A ^a   Driessen, J T N ^a   Maas, H A A M ^a   Wolfhagen, F H J ^a  

^a Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; VALPROIC ACID;

ADULT; AGED; AMMONIA BLOOD LEVEL; ARTERIAL BLOOD; ARTICLE; ARTIFICIAL VENTILATION; CASE REPORT; COMA; CONSCIOUSNESS DISORDER; DRUG USE; DRUG WITHDRAWAL; FEMALE; HUMAN; LIFE; METABOLIC ENCEPHALOPATHY; THREAT;

AGED, 80 AND OVER; AMMONIA; BRAIN DISEASES, METABOLIC; CONSCIOUSNESS DISORDERS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYPERAMMONEMIA; MIDDLE AGED; VALPROIC ACID;

EID: 39449089737     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Cotariu D, Zaidman JL. Valproic acid and the liver. Clin Chem. 1988;34:890-7.
2. Stephens JR, Levy RH. Valproate hepatotoxicity syndrome: hypotheses of pathogenesis. Pharm Weekbl Sci. 1992:14:118-21.
3. Weng TI, Shih FFS, Chen WJ. Unusual causes of hyperammonemia in the ED. Am J Emerg Med. 2004;22:105-7.
4. Informatorium medicamentorum. Den Haag: Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie; 2004. p. 223.
5. Murphy JV, Marquardt K. Asymptomatic hyperammonemia in patients receiving valproic acid. Arch Neurol. 1982;39:591-2.
6. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002;16:695-714.
7. Walstra GJM. Reversibele dementie bij gebruik van valproïnezuur. Ned Tijdschr Geneeskd. 1997;141:391-3.
8. Jongsma MJ, Snijders CJ. Valproïnezuur en stupor. Ned Tijdschr Geneeskd. 1990;134:2105-6.
9. Warter JM, Brandt Ch, Marescaux Ch, Rumbach L, Micheletti G, Chabrier G, et al. The renal origin of sodium valproate-induced hyperammonemia in fasting humans. Neurology. 1983;33:1136-40.
10. Marini AM, Zaret BS, Beckner RR. Hepatic and renal contributions to valproic acid-induced hyperammonemia. Neurology. 1988;38:365-71.
11. Verrotti A, Trotta D, Morgese G, Chiarelli F. Valproate-induced hyperammonemic encephalopathy. Metab Brain Dis. 2002;17:367-73.
12. Vossler DG, Wilensky AJ, Cawthon DF, Kraemer DLA, Ojemann LM, Caylor LM, et al. Serum and CSF glutamine levels in valproate-related hyperammonemic encephalopathy. Epilepsia. 2002;43:154-9.
13. Treem WR. Inherited and acquired syndromes of hyperammonemia and encephalopathy in children. Semin Liver Dis. 1994;14:236-58.
14. Hjelm M, Oberholzer V, Seakins J, Thomas S, Kay JD. Valproate-induced inhibition of urea synthesis and hyperammonaemia in healthy subjects. Lancet. 1986;2(8511):859.
15. Leão M. Valproate as a cause of hyperammonemia in heterozygotes with ornithine-transcarbamylase deficiency. Neurology. 1995;45(3 Pt 1):593-4.
16. Vries JE, Meurs AMB, Rubio-Gozalbo ME, Spaapen LJM, Gennip AH van. Een patiënt met ornitinetranscarbamoylasedeficiëntie: het fysiologische belang van de ureumcyclus. Nederlands Tijdschrift voor Klinische en Chemische Labgeneeskunde. 2003;28:313-7.
17. Hauser ER, Finkelstein JE, Valle D, Brusilow SW. Allopurinol-induced orotidinuria. A test for mutations at the ornithine carbamoyltransferase locus in women. N Engl J Med. 1990;322:1641-5.
18. Raskind JY, El-Chaar GM. The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother. 2000;34:630-8.
19. Gidal BE, Inglese CM, Meyer JF, Pitterle ME, Antonopolous J, Rust RS. Diet- and valproate-induced transient hyperammonemia: effect of L-carnitine. Pediatr Neurol. 1997;16:301-5.